▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Apr 16, 2014 by Todd Campbell

1 Stock Helping Revolutionize Diabetes Monitoring

New products in development with partners Johnson & Johnson and Tandem could help Dexcom outmaneuver its chief competitor, Medtronic.

Apr 15, 2014 by Todd Campbell

Earnings Roundup: Rite Aid Impresses

Here's what you need to know about Rite Aid's recent earnings and its plans to challenge market share leaders CVS and Walgreen.

Apr 15, 2014 by Todd Campbell

Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

Apr 15, 2014 by Todd Campbell

Better Buy: Illumina, Inc. Vs. Intuitive Surgical, Inc.

Investors have bid up shares in Illumina (ILMN) and Intuitive Surgical (ISRG) to frothy levels in the past. With markets off their highs, is one a better buy than the other?

Apr 14, 2014 by Todd Campbell

Impax Breathes New Life Into Stalled Parkinson's Drug

Impax's (IPXL) stumbles in bringing Rytary, it's long lasting Parkinson's drug, to market may finally be over given its re-filed with the FDA for approval.

Apr 13, 2014 by Todd Campbell

The Cost to Treat Cholesterol Plummets, But Will It Last?

Thanks to growing use of generics, spending on cholesterol treatments is falling. However, that may change once PCSK9 drugs from Amgen (AMGN), Regeneron (REGN), and Pfizer (PFE) reach the market.

Apr 12, 2014 by Todd Campbell

2 Ways To Invest in This 1 Big Spending Trend

Double digit growth in the largest category for drug spending may support Sanofi (SNY) and Merck (MRK) through 2016.

Apr 12, 2014 by Todd Campbell

Got Allergies? FDA to the Rescue

Spring flowers mean spring allergies and big bucks for an industry hoping to crack the allergy code.

Apr 12, 2014 by Todd Campbell

Warren Buffett Owns This Big Data Stock: Should You?

Verisk Analytics (VRSK), United Healthcare (UNH), and McKesson (MKC) are facing off with big data crunching solutions that could re-imagine healthcare markets.

Apr 11, 2014 by Todd Campbell

Here's What's Behind Puma's Crash

Puma Biotech (PBYI) is working on a promising breast cancer drug, but its shares are dropping sharply. Here's what you need to know about neratinib and why Puma investors got nervous.

Apr 11, 2014 by Todd Campbell

Are Celgene and Amgen Undervalued By the Market?

Celgene (CELG) and Amgen (AMGN) shares have fallen as investors have shifted away from biotech, but that may not mean they're cheap yet.

Apr 11, 2014 by Todd Campbell

Merck Shouts "Me, Too!" But Will It Matter?

Merck (MRK) joins Gilead (GILD), Bristol-Myers (BMY), and AbbVie (ABBV) in the race to cure hepatitis C, but Merck may end up trailing the pack.

Apr 10, 2014 by Todd Campbell

Stunning Spending Growth Prediction for Hepatitis C

New drugs from Gilead (GILD), Johnson & Johnson (JNJ), Bristol-Myers (BMY), and AbbVie (ABBV) have Express Scripts (ESRX) forecasting spending on hepatitis C drugs will double this year.

Apr 10, 2014 by Todd Campbell

3 Breast Cancer Drugs With Big Potential

CDK 4/6 Inhibitor breast cancer drugs from Pfizer (PFE), Novartis (NVS), and Lilly (LLY) are making their way through trials and may soon give patients and doctors a new, important weapon in HER2 positive breast cancer.

Apr 9, 2014 by Todd Campbell

Pharmacy Face-Off: Rite Aid, Walgreen, or CVS

With baby boomers aging and reform increasing the number of insured, pharmacy demand may be about to surge, but does that make Rite-Aid (RAD), Walgreen (WAG), or CVS (CVS) a better buy?

Apr 9, 2014 by Todd Campbell

1 Dividend-Friendly Biotech Play You Need to Know About

Red hot biotech demand for real estate in Massachusetts is juicing up demand for BioMed's (BMR) life sciences office and lab space.

Apr 7, 2014 by Todd Campbell

Is There a Lesson to Be Learned in Mallinckrodt's Questcor Deal?

Here's what you need to know about why Mallinckrodt bought the heavily shorted Questcor (QCOR) for more than $5.5 billion.

Apr 7, 2014 by Todd Campbell

The AACR Annual Meeting May Move These 2 Stocks

The American Association for Cancer Research meeting shines a bright light on gene testing like that performed by Myriad, and on promising late stage breast cancer treatments, including Pfizer's palbociclib.

Apr 4, 2014 by Todd Campbell

Better Buy: Medtronic, Inc. vs. Edwards Lifesciences Corp.

Medtronic (MDT) just released impressive data that suggests the number of transcatheter prodedures will climb, pitting Medtronic head to head against Edward's (EW) Sapient.

Apr 4, 2014 by Todd Campbell

3 Under-Loved Dividend Darlings for Your Portfolio

Drugmakers are a staple in dividend investors portfolios, but Bristol-Myers (BMY), Johnson & Johnson (JNJ), and Merck (MRK) may be among the best for investors to buy and hold.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services